Biotinylated Human IGSF8 Protein, Avitag?,His Tag (MALS verified)
分子別名(Synonym)
IgSF8,CD316,CD81P3,EWI-2,EWI2,KCT-4,LIR-D1,PGRL
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Biotinylated Human IGSF8 Protein, Avitag,His Tag (IG8-H82Q3) is expressed from human 293 cells (HEK293). It contains AA Arg 28 - Thr 579 (Accession # Q969P0).
Predicted N-terminus: Gly
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries an Avi tag (Avitag?) at the N-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 62.1 kDa. The protein migrates as 65-70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記(Labeling)
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
IGSF8(免疫球蛋白超家族成員8)是免疫球蛋白蛋白超家族EWI亞家族的成員,也稱(chēng)為EWI-2、KCT-4、LIR-D1和PGRL。它與四鏈蛋白CD81和CD9相互作用,可能調(diào)節(jié)它們?cè)谀承┘?xì)胞功能中的作用,包括細(xì)胞遷移和病毒感染。IGSF8與CD81協(xié)同抑制T細(xì)胞遷移,與CD82聯(lián)合抑制前列腺癌癥細(xì)胞遷移,以CD9和CD81為關(guān)鍵連接體調(diào)節(jié)表皮樣細(xì)胞在層粘連蛋白-5上的再聚集和運(yùn)動(dòng)。它還可能在整合素依賴(lài)的形態(tài)和運(yùn)動(dòng)功能中發(fā)揮作用,并可能參與成人大腦中神經(jīng)突起生長(zhǎng)的調(diào)節(jié)和神經(jīng)網(wǎng)絡(luò)的維護(hù)。最近的研究表明,IGSF8在具有抗原呈遞缺陷的惡性細(xì)胞上高度表達(dá),并與NK受體相互作用以抑制NK細(xì)胞的細(xì)胞毒性。
關(guān)鍵字: IGSF8;IGSF8蛋白;IGSF8重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶(hù)超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。